173 related articles for article (PubMed ID: 10500817)
21. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.
Wartman LD; Fiala MA; Fletcher T; Hawkins ER; Cashen A; DiPersio JF; Jacoby MA; Stockerl-Goldstein KE; Pusic I; Uy GL; Westervelt P; Vij R
Leuk Lymphoma; 2016; 57(3):728-30. PubMed ID: 26674111
[No Abstract] [Full Text] [Related]
22. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
23. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia.
Styczyński J; Wysocki M; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk A; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Neoplasma; 2002; 49(3):178-83. PubMed ID: 12098004
[TBL] [Abstract][Full Text] [Related]
24. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
26. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
27. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM; Berman E; Maraone MP; Ganzina F
Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: a report of the Children's Cancer Group.
Ettinger LJ; Ivy P; Gaynon PS; Ettinger AG; Liu-Mares W; Krailo MD
Cancer; 1997 Jul; 80(2):311-6. PubMed ID: 9217045
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.
Styczynski J; Wysocki M
Pediatr Blood Cancer; 2004 Feb; 42(2):195-9. PubMed ID: 14752887
[TBL] [Abstract][Full Text] [Related]
30. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
Frost BM; Gustafsson G; Larsson R; Nygren P; Lönnerholm G
Leukemia; 2000 May; 14(5):943-4. PubMed ID: 10803530
[No Abstract] [Full Text] [Related]
31. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
32. In vitro chemosensitivity testing in acute leukemias. Results of a retrospective study.
Lepri E; Liberati M; Menconi E; Santucci A; Piselli F; Barzi A
Anticancer Res; 1990; 10(6):1735-8. PubMed ID: 2285251
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Badar T; Shetty A; Bueso-Ramos C; Cortes J; Konopleva M; Borthakur G; Pierce S; Huang X; Chen HC; Kadia T; Daver N; Dinardo C; O'Brien S; Garcia-Manero G; Kantarjian H; Ravandi F
Am J Hematol; 2015 Sep; 90(9):769-73. PubMed ID: 26017166
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein expression in patients with acute leukemia-clinical relevance.
Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gieseler F; Diem H; Ledderose G; Gullis E; Sauer H; Wilmanns W
Leukemia; 1996 Jul; 10 Suppl 3():S23-S31. PubMed ID: 8656697
[TBL] [Abstract][Full Text] [Related]
35. [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults].
Styczyński J; Haus O
Postepy Hig Med Dosw (Online); 2006; 60():527-37. PubMed ID: 17060894
[TBL] [Abstract][Full Text] [Related]
36. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis.
Lathan B; von Tettau M; Verpoort K; Diehl V
Haematol Blood Transfus; 1990; 33():295-8. PubMed ID: 1691133
[No Abstract] [Full Text] [Related]
37. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
38. Glucocorticoid resistance in childhood leukemia.
Kaspers GJ; Pieters R; Klumper E; De Waal FC; Veerman AJ
Leuk Lymphoma; 1994 Apr; 13(3-4):187-201. PubMed ID: 8049644
[TBL] [Abstract][Full Text] [Related]
39. Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles.
Singh A; Myklebust NN; Furevik SMV; Haugse R; Herfindal L
Curr Med Chem; 2019; 26(28):5278-5292. PubMed ID: 31099318
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
